BioNxt Solutions Inc.
VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary Cladribine product for the treatment of Multiple Sclerosis ("MS") has been completed. Results will be reported by the Company when available. The PK study closely follows the unanimously successful results of the ODF Cladribine toxicity study, announced February 7, 2024.
BioNxt is developing a proprietary hybrid-generic ODF Cladribine dosage form, directed at the MS market. Cladribine tablets are approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The comparative PK study was carried out by a European contract research organization in accordance with EU medical regulatory guidelines using animal models and a single administration of either sublingual (ODF) or oral (tablet) Cladribine. Blood testing and analysis was carried out pre-dose and at up to six time points after administration using blood aliquots.
BioNxt has accelerated its Cladribine ODF program in a priority manner with GMP product development and batch production planned for Q1 and Q2 2024 with the European Investigational Medicinal Product Dossier (IMPD) preparation and submission planned for Q2 2024.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
BioNxt's wholly owned subsidiary is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sublingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global pharmaceutical drug delivery market size was valued at USD 1,525 billion in 2022 and expected to surpass approximately USD 2,047 billion by 2030.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Declares Quarterly Dividend5.2.2025 07:50:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 5, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on February 28th to shareholders of record at the close of business on February 17th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's o
Preservica and Oyster IMS Partner to Future-Proof Microsoft 365 Data with Active Digital Preservation5.2.2025 04:00:00 CET | Press release
OXFORD, UK / ACCESS Newswire / February 5, 2025 / Preservica, the leader in Active Digital Preservation™ archiving, has today announced a partnership with Oyster IMS, an expert consultancy-led business serving transnational agencies, global enterprises, local authorities and SMEs. Oyster IMS is now an authorized reseller of Preservica's Enterprise and Preserve365® technology and will support Microsoft 365 customers adopting a strong information governance framework for high-value, long-term content and those preparing for AI implementations. As digital content continues to grow in volume and complexity, having a robust and secure foundation of instantly useable, reliable and trusted long-term data has become a strategic imperative, essential for cutting compliance risk and leveraging AI. This is the arena in which Oyster IMS works with a set of clients ranging from SMEs to multinationals, and from local authorities to international governmental bodies. "I'm delighted to establish a for
ToolsGroup Welcomes Supply Chain Leader Sean Elliott as Chief Executive Officer4.2.2025 15:15:00 CET | Press release
20-year industry veteran brings deep technical expertise and leadership to guide ToolsGroup's next phase of growth BOSTON, MA / ACCESS Newswire / February 4, 2025 / ToolsGroup, a global leader in supply chain and retail planning and optimization software, today announced the appointment of Sean Elliott as its new Chief Executive Officer, effective immediately. Elliott brings more than two decades of strategic leadership and technical expertise in supply chain software development and leadership to ToolsGroup. Most recently, he served as Co-CEO at Körber Supply Chain Software. At ToolsGroup, Elliott will focus on accelerating innovation, driving strategic business expansion, and strengthening its partnerships and ecosystem to deliver a best-in-class customer outcome and experience. "We are thrilled to welcome Sean to ToolsGroup," said Andrew Zbella, Principal at Accel-KKR and member of the Board of Directors. "His proven leadership, deep technical background and continued commitment to
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment4.2.2025 05:00:00 CET | Press release
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth. ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collab
IXOPAY Appoints Yasser Abou-Nasr as SVP of Product to Drive Execution and Scale4.2.2025 00:00:00 CET | Press release
Seasoned Fintech Leader Joins IXOPAY to Advance Product Innovation and Drive Scalable Growth in Payment Orchestration. LEHI, UT / ACCESS Newswire / February 4, 2025 / IXOPAY, a leading enterprise payment orchestration platform, announced the appointment of Yasser Abou-Nasr as SVP of Product. With over 16 years of senior product leadership in payments and fintech, Yasser joins IXOPAY to execute the company's strategic vision and scale its product offerings to meet the growing demand for seamless and secure payment solutions. Yasser brings a proven track record of driving product execution at scale, combined with deep expertise in product management, operational transformation, and the development of B2B SaaS platforms. His leadership will be instrumental in advancing IXOPAY's enterprise payment orchestration platform, enabling businesses worldwide to simplify, secure, and optimize their payment systems through scalable and flexible solutions. "Yasser's ability to execute and scale compl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom